Evidence map›Paper›PMID 40400957›Full record

ArticleJournal of thoracic disease2025

Machine learning algorithms for predicting malignancy grades of lung adenocarcinoma and guiding treatments: CT radiomics-based comparisons.

Jun Zhu, Jiayu Tao, Fengfeng Zhang, Jie Yao, Ke Chen, Yuxuan Wang, Xiaochen Lu, Bin Ni, Maoshan Zhu

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jun Zhu *Department of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, China.ORCID https://orcid.org/0009-0009-1276-1927
Jiayu Tao *Department of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Fengfeng Zhang *Department of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Jie YaoDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, China.
Ke ChenDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, China.
Yuxuan WangDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaochen LuDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, China.
Bin NiDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, China.
Maoshan ZhuDepartment of Thoracic Surgery, Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine, Lianyungang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung adenocarcinoma (LUAD) is the most frequently diagnosed subtype of non-small cell lung cancer (NSCLC). Notably, prognosis can vary significantly among LUAD patients with different tumor subtypes. The advent of radiomics and machine learning (ML) technologies enables the development of non-invasive pathology predictive models. We attempted to develop computed tomography (CT) radiomics-based diagnostic models, enhanced by ML, to predict LUAD malignancy grade and guide surgical strategies. Methods: In this retrospective analysis, a total of 168 surgical patients with histology-confirmed LUAD were divided into low-risk group (n=93) and intermediate-to-high-risk group (n=75) based on postoperative pathology. The region of interest (ROI) was delineated on the preoperative CT images for all patients, followed by the extraction of radiomic features. Patients were randomly allocated to a training set (n=117) and a testing set (n=51) in a 7:3 ratio. Within the training set, clinical-radiological model (CM) and radiomics model (RM) were developed utilizing patients' clinical characteristics, radiological semantic features, and radiomic features, along with the calculation of Rad scores. After the Rad scores were combined with independent risk factors among clinical-radiological features, logistic regression (LR), decision tree (DT), random forest (RF), extreme gradient boosting (XGBoost), support vector machine (SVM), K-nearest neighbors (KNN), and naïve Bayes model (NBM) were employed to create different comprehensive models (COMs). The optimal model was identified based on the receiver operating characteristic (ROC) curves and the DeLong test. Finally, Shapley additive explanations (SHAP) were utilized to visualize the predictive processes of the models. Results: Among the 168 patients enrolled, there were 50 males (29.76%) aged 56 (49.25, 67.00) years and 118 females (70.24%) aged 56.5 (42.00, 64.00) years; Diameter (P<0.001), and consolidation-to-tumor ratio (CTR) ≥0.5 (P=0.002) were identified as independent risk factors for the malignancy degree of LUAD during CM creation. The CM had an area under the ROC curve (AUC) of 0.909 [95% confidence interval (CI): 0.856-0.962] in the training set and 0.920 (95% CI: 0.846-0.994) in the testing set. The RM, comprising seven radiomic features, achieved an AUC of 0.961 (95% CI: 0.926-0.996) in the training set and 0.957 (95% CI: 0.905-1.000) in the testing set. Among models created using various ML algorithms, the XGBoost model was identified as the optimal model. SHAP visualization revealed the model prediction processes and the values of different features. Conclusions: We constructed and validated a robust, integrative model leveraging ML and CT radiomics, which amalgamates radiomics, clinical, and radiological attributes to precisely identify LUADs with elevated postoperative pathological grades. This enables doctors to formulate different surgical plans according to the pathology of the patients' tumors before the operation.

Indexed as

lung cancerlung nodulesprediction modelRadiomics

Identifiers

PMID40400957
PMCPMC12090144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.